Table 1.
Extracellular proteins as anti-cancer mAb targets validated in the clinic
| Target | Therapeutic indication(s) | References |
|---|---|---|
| CD19 | Precursor cell lymphoblastic leukemia-lymphoma | [87] |
| CD20 | Relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin lymphoma (NHL) | [88] |
| CD22 | B-cell acute lymphoblastic leukemia | [89] |
| CD30 | Hodgkin lymphoma (HL), systemic anaplastic large cell lymphoma | [90] |
| CD33 | AML | [91] |
| CD38 | Multiple myeloma | [92] |
| CD52 | B-cell chronic lymphocytic leukemia | [93] |
| CTLA-4 | Melanoma | [94] |
| EGFR | Carcinoma, non-small-cell lung | [95] |
| EpCAM | Head and neck cancer | [96] |
| GD2 | Neuroblastoma | [97] |
| HER2 | Breast cancer | [98] |
| PD-1 | Carcinoma; non-small-cell lung carcinoma; renal cell Hodgkin disease melanoma | [99], [100] |
| PDGFR-α | Sarcoma | [101] |
| PD-L1 | Metastatic Merkel cell carcinoma | [102], [103] |
| SLAMF7 | Multiple myeloma | [104] |
| VEGF | Stomach neoplasms | [95], [105], [106] |